|Videos|January 30, 2023
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Author(s)Loretta J. Nastoupil, MD, Marc S. Hoffmann, MD
Loretta J. Nastoupil, MD, reviews data from the ZUMA-7 trial investigating the use of axicabtagene ciloleucel as a second-line therapy for large b-cell lymphoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Dostarlimab monotherapy produced a 27% response rate in PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
A rituximab biosimilar has been approved by the FDA.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
Advertisement
Advertisement
Trending on OncLive
1
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
2
Expanding Options and Long-Term Data Reshape Frontline and Emerging CLL Treatment Strategies
3
FDA Flashback: GI Cancer Decisions and News From July 2026
4
TNFR2 Advances as a Novel Target for Restoring Antitumor Immunity Across Lymphoma and Solid Tumors
5